Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?
Objective: Angiotensin II receptor blockers (ARBs) and angiotensin-converting enzyme (ACE) inhibitors are known to reduce proteinuria and have been the first-line agents in the management of diabetic nephropathy for the past 20 years. This review covers recent studies that compare the benefit of add...
Saved in:
Main Authors: | Eva Vivian (Author), Chelsea Mannebach (Author) |
---|---|
Format: | Book |
Published: |
BioExcel Publishing Ltd,
2013-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway
by: Yusong Nie, et al.
Published: (2020) -
Nanopore-based full-length transcriptome sequencing for understanding the underlying molecular mechanisms of rapid and slow progression of diabetes nephropathy
by: Jing E, et al.
Published: (2024) -
Slow on the Uptake, Progression to Heartbreak
by: Ashley K. Binder MD, et al.
Published: (2020) -
Mesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
by: Janaina Paulini, et al.
Published: (2016) -
Effect Of Antioxidant To Progression Of Diabetic Nephropathy In Diabetic Rat
by: Ki Sung Kang, et al.
Published: (2012)